A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

Abroad (travel likely)Recruiting

Conditions

Chronic Spontaneous Urticaria

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Novartis, East Hanover, New Jersey, United States

Study leads

Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous Urticaria

Abroad (travel likely)RecruitingPHASE1, PHASE2

Wuhu, China · Beijing, China

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)

Abroad (travel likely)RecruitingPHASE2

North Miami Beach, United States · Glenview, United States

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

Chronic Spontaneous Urticaria (CSU)

Abroad (travel likely)RecruitingPHASE3

Birmingham, United States · Birmingham, United States

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

Chronic Spontaneous Urticaria

Abroad (travel likely)RecruitingPHASE2

Phoenix, United States · Little Rock, United States